Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

80.0%

4 terminated/withdrawn out of 5 trials

Success Rate

20.0%

-66.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(40.0%)
Phase 1
2(40.0%)
Phase 3
1(20.0%)
5Total
Phase 2(2)
Phase 1(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00982215Phase 1Completed

Pilot Study of Pharmacology of Paracetamol Administered Per-oral Mucosa

Role: collaborator

NCT00034372Phase 2Terminated

Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma

Role: lead

NCT00050375Phase 3Terminated

Clinical Trial for Ovarian Cancer (OvaRex®)

Role: lead

NCT00034138Phase 1Terminated

A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma

Role: lead

NCT00086632Phase 2Terminated

Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment

Role: lead

All 5 trials loaded